The 14 Acquired Biological Capabilities That Define All Malignant Tumors

Of the roughly 37 trillion cells in the human body, a healthy cell must obey strict biological rules: divide only when instructed, stay in its designated tissue, and self-destruct if its DNA becomes irreparably damaged. A malignant tumor is simply a cell that has systematically broken 14 specific rules.[6]

The National Cancer Institute defines cancer as a disease in which "some of the body’s cells grow uncontrollably and spread to other parts of the body." But beneath that simple definition lies a complex web of survival strategies that researchers have spent decades decoding.[6]

In the year 2000, researchers Douglas Hanahan and Robert Weinberg published a landmark paper in the journal Cell that sought to reduce the vast complexity of oncology into a logical framework. They proposed six original "Hallmarks of Cancer."[8]

These initial six capabilities focused heavily on the internal machinery of the rogue cell. They included sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis (building new blood vessels), and activating invasion and metastasis.[8]

"The hallmarks of cancer comprise an organizing principle for rationalizing the complexities of neoplastic disease," Hanahan wrote, explaining the goal of the framework. It shifted the scientific focus from the anatomical location of the tumor to its underlying biological behavior.[1]

By 2011, as targeted therapies emerged and tumors demonstrated their ability to adapt, the framework required an update. Hanahan and Weinberg expanded the list to 10 hallmarks, adding the reprogramming of energy metabolism and the evasion of immune destruction.[2]

They also identified two "enabling characteristics" that accelerate the acquisition of the other hallmarks: genome instability and tumor-promoting inflammation.[2]

The recognition of immune evasion as a core hallmark fundamentally changed modern treatment. It provided the conceptual grounding for immunotherapies, which do not target the tumor directly but rather remove the chemical brakes the tumor places on the host's immune system.[4]

In 2022, writing in Cancer Discovery, Hanahan expanded the framework again, adding four new dimensions that reflect a shift toward viewing cancer as an "eco-evolutionary" process rather than just a genetic defect.[1][7]

The first new dimension is unlocking phenotypic plasticity. This is the tumor's ability to change its cellular identity. For example, a melanoma cell might revert to an embryonic-like state to escape a targeted drug designed specifically for mature skin cells.[1]

The second is nonmutational epigenetic reprogramming. Cancer cells can alter how their genes are read and expressed without changing the underlying DNA sequence, allowing them to rapidly adapt to therapeutic stress in real time.[1]

The third addition, the polymorphic microbiome, highlights the systemic nature of the disease. Research now shows that the bacteria and fungi living in the gut, and even within the tumors themselves, actively influence tumor progression and dictate how well a patient responds to immunotherapy.[1][4]

The final new hallmark involves senescent cells. Paradoxically, cells that have permanently stopped dividing—often as a result of chemotherapy or radiation—can secrete inflammatory signals that inadvertently promote the growth and survival of neighboring cancer cells.[1]

Today, these 14 hallmarks serve as a direct roadmap for drug development. Instead of searching for a single universal cure, oncologists use the framework to design combination therapies that block multiple survival pathways simultaneously.[4]

For example, combining an angiogenesis inhibitor to block blood vessel growth with an immune checkpoint inhibitor to prevent immune evasion attacks the tumor's infrastructure and its defense system at the exact same time.[4]

Researchers are also investigating how specific compounds can alter these basic hallmarks. Studies on ginsenosides, for instance, explore how modifying metabolic and inflammatory pathways might offer complementary approaches to standard treatments.[5]

The framework continues to evolve. As researchers map the tumor microenvironment in greater detail, the next frontier is predicting how a tumor will adapt its hallmarks in response to a specific therapy.[7]

By anticipating the cancer's next evolutionary move, clinicians aim to sequence therapies in a way that cuts off the tumor's escape routes before it can use them.[7]